JAB-23E73 Trial
Phase 1/2
294
about 2.8 years
18+
4 sites in MN, MO, OH +1
What this study is about
Researchers are testing JAB-23E73 in adults with advanced solid tumors that have a KRAS alteration. The trial will evaluate the safety and tolerability of this medication as a single treatment.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take JAB-23E73
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Dose Escalation (Phase 1a): Determine the Maximum tolerated dose (MTD) of JAB-23E73 monotherapy., Dose Escalation (Phase 1a): Evaluate the overall safety and tolerability of JAB-23E73.
Secondary: Dose Escalation (Phase 1a): Overall Response Rate (ORR), Dose Escalation (Phase 1a): Pharmacokinetics (PK): Maximum Observed Concentration (Cmax), Dose Expansion/Optimization (Phase 1b): Evaluate the overall safety and tolerability of JAB-23E73., Dose Expansion/Optimization (Phase 1b): Overall Response Rate (ORR), Dose Expansion/Optimization (Phase 1b): Pharmacokinetics (PK): Maximum Observed Concentration (Cmax)